CA Patent

CA2949816A1 — Methods for assessing responsiveness to asthma treatment based on vnn-1 expression and promoter methylation

Assigned to Cincinnati Childrens Hospital Medical Center · Expires 2015-11-19 · 10y expired

What this patent protects

Provided herein are methods and kits related to use of vanin-1 (VNN1) expression for assessing responsiveness to steroid treatment in subjects with asthma and for treating subjects with asthma.

USPTO Abstract

Provided herein are methods and kits related to use of vanin-1 (VNN1) expression for assessing responsiveness to steroid treatment in subjects with asthma and for treating subjects with asthma.

Drugs covered by this patent

Patent Metadata

Patent number
CA2949816A1
Jurisdiction
CA
Classification
—
Expires
2015-11-19
Drug substance claim
No
Drug product claim
No
Assignee
Cincinnati Childrens Hospital Medical Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.